<p>The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors all reports of suspected adverse drug reactions (ADRs) via the Yellow Card Scheme, including those reported in association with use for assisted reproduction such as in vitro fertilisation (IVF). These include reports of licensed and off-label use of medicines to suppress the natural menstrual cycle, medicines to prepare and stimulate the ovaries for ovulation, medicines at the time of egg collection and embryo transfer and medicines used to support the placenta during early pregnancy. The doses of each medicine used are set out in the product information of licensed medicines and are considered as part of the evaluation process when a potential safety concern is reviewed. A suspected ADR may be reported at any time after the medicine has been taken.</p><p>European Union legislation requires Member States to provide spontaneous reporting systems for ADRs to medicines. Such systems are widely used internationally for collection of suspected adverse reactions.</p><p>Data from the register of patients and treatments, maintained by the Human Fertilisation and Embryology Authority (HFEA), is already used for research on the long-term health implications of medicines administered during IVF. Among the research projects that have been conducted using HFEA register data are studies that looked at the cancer risk for women undergoing fertility treatment and children born as a result of assisted reproduction.</p>